We have also tried out grading systems such as the confidence and competence scales (where key surgical skills are graded on a scale of 0-5 by students and supervisors alike) and periodic feedback called "My day at JCOC" (where students are encouraged to offer suggestions to improve the quality of training). Both of these are analyzed and the results and action measures are discussed with them.
A little bit of motivation goes a long way in retaining interest in both the student and the teacher.
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Intravitreal bevacizumab
Sir, It was interesting reading the guest editorial and the special editorial in the July issue of IJO. [1] I would like to point out that a pack of Lucentis includes 5 µ needle filter in spite of the fact that it contains a single dose. This is not provided with bevacizumab.
Five-micron filter provided with Lucentis will not allow administration of larger particles. Large particles are known to be formed with protein containing products such as bevacizumab. [2] Such particles are known to induce inflammation and sterile endophthalmitis. [3] The use of 5 µ needle filter will probably help in avoiding sterile endophthalmitis (culture negative) which are also seen in a cluster, even when multiple doses are removed from the same vial in one sitting with due precautions. [3, 4] Generally, bevacizumab is not known to be contaminated after multiple punctures, which has been demonstrated earlier by research. [5] However, if desired, potential contamination can also be eliminated using multidose vial adaptors as demonstrated by French investigators. [6] They used multidose vial adaptor having two distinct air and fluid channels. Air channel contains 0.45 µ air filter to prevent entry of microorganisms in a multidose vial and fluid channel containing 5 µ fluid filter to avoid withdrawal of large size particles.
Can this be recommended to take advantage of existing knowledge to provide affordable care to needy patients? This is more pertinent now as we have more than one manufacturer of bevacizumab in our country.
Comment on: "Case report of a secondary macular hole closure after intravitreal bevacizumab therapy in a patient with retinal pigment epithelial detachment"
Sir, I read with interest the case report on the closure of a macular hole over a serous retinal pigment epithelial detachment (PED) with intravitreal bevacizumab. [1] I want to humbly discuss a few facts.
The role of anti-vascular endothelial growth factor (anti-VEGF) agents in serous PED without subretinal or intraretinal fluid or active choroidal neovascular membrane/ idiopathic polypoidal choroidal vasculopathy may require further research. In the present case, [1] the shallow subretinal fluid at one margin of the macular hole could have been related to the macular hole itself or the mechanical effect of the high PED. In such a scenario, fundus fluorescein angiogram and indocyanine green angiogram would add significant scientific value and justification for the use of bevacizumab in this case, if they are available. Furthermore, we need to consider the fact that intravitreal anti-VEGF agents can cause retinal pigment epithelial tears [2] in cases of high serous PEDs. The rare but potentially blinding complications of intravitreal anti-VEGF agents such as endophthalmitis [3] and retinal detachment should be kept in mind. The goal of management with intravitreal bevacizumab in the presented case [1] may need elucidation. A history of systemic or local steroid use is also relevant in the presented case, as central serous chorioretinopathy, though unlikely in a 73 year old, needs to be ruled out.
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